A. Y. Bedikian
About
In The Last Decade
A. Y. Bedikian
24 papers receiving 505 citations
Peers
Comparison fields: 5 of 54
- Oncology 390
- Molecular Biology 234
- Immunology 131
- Epidemiology 86
- Ophthalmology 61
Countries citing papers authored by A. Y. Bedikian
This map shows the geographic impact of A. Y. Bedikian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Y. Bedikian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Y. Bedikian more than expected).
Fields of papers citing papers by A. Y. Bedikian
This network shows the impact of papers produced by A. Y. Bedikian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Y. Bedikian. The network helps show where A. Y. Bedikian may publish in the future.
Co-authorship network of co-authors of A. Y. Bedikian
This figure shows the co-authorship network connecting the top 25 collaborators of A. Y. Bedikian. A scholar is included among the top collaborators of A. Y. Bedikian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Y. Bedikian. A. Y. Bedikian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 7 | |
| 4 | 1 | |
| 5 | 10 | |
| 6 | 2 | |
| 7 | 1 | |
| 8 | A phase I and pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III /IV melanoma | 3 |
| 9 | 7 | |
| 10 | 9 | |
| 11 | 2 | |
| 12 | 1 | |
| 13 | 5 | |
| 14 | 1 | |
| 15 | 40 | |
| 16 | 230 | |
| 17 | 21 | |
| 18 | 62 | |
| 19 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. | 2 |
| 20 | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.